• Publications
  • Influence
Establishment of a human pancreatic tumor xenograft model: potential application for preclinical evaluation of novel therapeutic agents.
Adenocarcinoma of the pancreas is currently the fifth leading cause of death in the United States. It remains generally incurable by available treatment modalities. We report here on theExpand
  • 42
  • 2
Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.
We have previously reported that bryostation 1 (Bryo 1) induces differentiation of chronic lymphocytic leukemia (CLL) in vitro to a hairy cell (HC) stage. This study tests the hypothesis that BryoExpand
  • 43
  • 1
  • PDF
Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.
We tested the activity of dolastatin 10 (a natural product derived from the shell-less marine mollusk, Dolabella auricularia, a sea hare) and its structural modification, auristatin PE, alone and inExpand
  • 45
  • 1
  • PDF
Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma
We studied the antitumor effects of dolastatin 10, its structural modification, auristatin PE (TZT-1027), and vincristine alone and in combination with bryostatin 1 on a human diffuse large cellExpand
  • 20